d Proteomics Approach. J Proteome Res. 2012 Dec 12.
33. Ernst WA, Kim HJ, Tumpey TM, Jansen ADA, Tai W, Cramer DV, et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine. 2006;24(24):5158-68.
34. Gattoc, Nair, Ault. Human Papillomavirus Vaccination. Vaccine. 2013;6(15):85.-8545
35. Liaw K.L., Hildesheim A., Burk R.D., Gravitt P., Wacholder S., et al. A prospective study of human papillomavirus (I-IPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other l-IPV types. Infect Dis 2001; 183:8-15.
36. de Sanjose S., Palefsky J., Cervical and anal 1-IPV infections in HIV positive women and men. Virus Res 2002; 89:201-211.
37. Christensen N.D., Reed C.A., Cladel N.M., Han R., Kreider J.W., et al. Immunization with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomaviruses. J Virol 1996; 70:960-965.
38.Syrjanen KJ and Syrjanen SM. Papillomavirus Infections in Human Pathology.UK: John Wiley & Sons Ltd;2000.
39. Shope R.E., Hurst E.W., Infectious papillomatosis of rabbits; with a note on the Histopatholoily. J E.vp Med 1933; 58:607-624.
40. Green Ivi, Breackmann KH, Sanders PR, Loewenstein PM, Freel JH, Eisinger M, and Switlyk SA. Isolation of a human papillomavirus from a patient with epidermo dysplasia verruciformis: presence of related viral DNA genomes in human urogenital tumors. Proc Natl Acad Sci USA 1982; 79(14): 4437-4441.
41. Lehn H, Krieg P, Sauer. Papillomavirus genomes in human cervical tumors: analysis of their transcriptional activity. Proc Natl Acad Sci USA 1985; 82(16): 5540-5544.
42. Tsunokawa Y, Takebe N, Kasamatsu T, Terada M, and Sugimura T. Transforming Activity of Human Papillomavirus Type 16 DNA Sequences in a Cervical Cancer. Proc Natl Acad Sci USA 1986; 83(7): 2200-2203
43. Smotkin D, Wettstein FO. Transcription of Human Papillomavirus Type 16 Early Genes in a Cervical Cancer and a Cancer-Derived Cell Line and Identification of the E7 Protein. Proc Natl Acad Sci USA 1986; 83(13): 4680-4684.
44. Munger K, Phelps WC, Bubb V, Howley PM, and Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989; 63( 10): 4417-4421.
45. Watanabe 5, Kanda T, and Yoshike K. Human Papillomavirus Type 16 Transformation of Primary Human Embryonic Fibroblasts Requires Expression of Open Reading Frames E6 and E7. J Virol 1989; 63(2): 965-969.
46. McCance DJ, Kopan R, Fuchs E, Laimins LA. Human Papillomavirus Type 16 Alters Human Epithelial Cell Differentiation in vitro. Proc Natl Acad Sci USA 1988; 85(19): 7169-7173.
47. Resnick RM, cornelissen MTE, Wright DK, Eichinger GH, Fox HS, Schegget J, Manos MM. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst 1990; 82: 1477-1484.
48. Chen L, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 1991; 88: 110-114.
49. Tindle RW, Fernando GJP, Sterling JC, and Frazer IH. A public T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci USA 1991; 88: 5887-5891.
50. Evander M, Edlund K, Boden E, Gustafsson A, Jonsson M, and Karlsson R, Rylander E, Wadell G. Comparison of a one-stop and a two-stop .polymerase chain reaction with degenerate general primers
51. Heck DV, Yee CL, Howley PM, and Munger K. Efficacy of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci USA 1992; 89: 4442-4446.
52. Chan SY, Delius H, Halpern A, and Bernard HU. Analysis of genomic sequences of 95papillomavirus types: Uniting typing, phylogeny, and taxonomy. J Virol 1995; 69(5): 3074-3083.
53. Jacobs MV, Snijders PJF, Brule AJC, Helmerhorst TJM, Meijer CJLM.. and Walboomers JMM. A general primer GP5+/GP6+ -mediated PCR enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. .1 Clin Microbiol 1997; 35(3): 791-795.
54. Cope TU, Hildesheim A, Schiffrnan MH, Manos MM, Lorincz AT, Burk RD, Glass AG, Greer C,Buckland J, Helgesen K, Scott DR, Sherman ME, Kurman RJ, and Liaw KL. Comparison of the hybrid capture tube test and PCR for detection of human papillomavirus DNA in cervical specimens. J Clin Microbiol 1997; 35(9): 2262-2265.
55. Meschede W, Zumbach K, Braspenning J, Scheffner M, Benitez-Bribiesca L, Luande J, and PawIlia NI. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol 1998; 36(2): 475-480.
56. Zazove P, Reed BD, Gregoire L, Ferenczy A, Gorenflo DW, and Lancaster WD. Low false-negative rate of PCR analysis for detecting human papillomavirus-related cervical lesions. J Clin Microbial 1998; 36(9): 2708-2713.
57. Shi W, Bu p, Liu J, Polack A, Fisher S, and Qiao L. Human papillomavirus type 16 E7 DNA vaccine: Mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and anti tumor activity. J Virol 1999; 73(9): 7877-7881.
58. Kadish AS, Timmins P. Wang Y, Ho GYF, Burk RD, Kets J, He W, Romney SL, Johnson A, Angeletti R, Abadi M. Regression of cervical interaepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomark Prey 2002; 11: 483-488.
59. Leachman SA, Bryan M, Slade MD, Levine D, Sundaram RK, Xiao W, Bryan M, Zelterman D, Tiegelaar RE, and Brandsma JL. Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J Virol 2002; 76(15): 7616-7624.
60. Lin CT, Hung CF, Juang J, He L, Lin KY, Kim TW, We TC. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies and anti tumor effects of HPV-16 E7- expressing sindbis virus replicon particles. Mol Ther 2003; 8(4): 559-566.
61. Kotecha MT, Afghan RK, Vasilikopoulou E, Wilson E, Marsh P, Kast WM, Davies DH, CaparrosWanderley W. Enhanced tumour growth after DNA vaccination against human papillomavirus E7 oncoprotein: evidence for tumor-induced immune deviation. Vaccine 2003; 21: 2506-2515.
62. Lefevre J, Hankins C, Pourreaux K, Voyer H, Coutlee F. Real-time PCR assays using internal controls for quantitation of 1-12V-16 and B-globin DNA in cervicovaginal lavages. J Virologic Meth 2003; 114: 135-144.
63. Cheung Y-K, Cheng SCS, Sin FWY, and Xie Y. Plasmid encoding papillomavirus type 16 (HPV 16) DNA constructed with codon optimization improved the immunogenicity against HPV infection. Vaccine 2004; 23:629-638.
64. Peng S, Ji H, Trimble C, He L, Tsai Y-C, Yeatermeyer J, Boyd DAK, Hung CF, and Wu TC. Development of a DNA Vaccine Targeting Human Papillomavirus Type 16 Oncoprotein E6. J Virol 2004; 78(16): 8468-8476.
65. Hallez S, Simon P, Maudoux F, Doyen J, Noel JC, Beliard A, Lagrost AC,Hubert P, Gerday C, Burry A, Boniver J, Foidart JM, Delvenne P, and Jacobs N. Phase VII trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic positive cervical intraepithelial neoplasia. Cancer Immunol Immunother 2004; 53: 642-650.
66. Huh KW, DeMasi J, Ogawa H, Nakatani Y, Howley PM, and Munger K. Association of the human papillomavirus type 16 E7 oncoprotein with the 600-KDa retinoblastoma protein-associated factor p600. Proc Natl Acad Sci USA 2004; 102(32): 11492-11497.
67. Yang H, Yang K, Khafagi A, Tang Y, Carey TE, Opipari AW, Lieberman R, Oeth PA, Lancaster W, Klinger HP, Kaseb AO, Metwaily A, Khaled H, and Kumit DM. Sensitive detection of human papi
llomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies. Proc Natl Acad Sci USA 2005; 102(21): 7683-7688.
68. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A.
69. Doorbar J., The papillomavirus life cycle. J Clin virol 2005, 32: 7-i 5.
70. Flores ER, Allen-Hoffmann BL, Lee D, and Lambert PF. The Human Papillomavirus Type 16 E7Oncogene Is Required for the Productive Stage of the Viral Life Cycle. J Virol 2000; 74(14): 6622-6631.
71. Minson AC. Human papilomaviruse. In: Topley wilson’s microbiology and microbial infections, Ninth ed. Virology, UK: Arnold Pub London; 1998.
72. Yaltirik M, Ozveren A, Alatli C, and Buyukakyuz N. Detection of human papillomavirus in benign, malignant and pre-cancerous lesions of oral mucosa by in situ hybridization. Turk J Med Sci 2001; 31: 509-515.
73. Khan MA, Tolleson WH, Gangemi JD, and Pirisi L. Inhibition of growth, transformation, and expression of human papillomavirus type 16 E7 in human keratinocytes by alpha interferons. J Virol 1993; 67(6): 3396-3403.
74. Akerman GS, Tolleson WH, Brown ILL, Zyzak LL, Mourateva E, Engin TSW, Basaraba A, Coker AL, Creek KE, and Pirisi L. Human Papillomavirus Type 16 E6 and E7 Cooperate to Increase Epidermal Growth Factor Receptor (EGFR) mRNA Levels, Overcoming Mechanisms by which Excessive EGFR Signaling Shortens the Life Span of Normal Human Keratinocytes. Cancer Res 2001; 61: 3837-3843
75. Lewis H, Webster K, Sanchez-Perez AM, and Gaston K, Cellular transcription factors regulate human papillomavirus type 16 gene expression by binding to a subset of the DNA sequence srcognized by viral E2 protein. J Gen Virol 1999; 80: 2087-2096.
76. Jeckel S, Huber E, Stubenrauch F, and Inner T. A transactivator function of cottontail rabbit papillomavirus E2 is essential for tumor induction in rabbits. J Virol 2002; 76(22):

دسته‌ها: پایان نامه ها

دیدگاهتان را بنویسید